Home
Issues
2018
April 2018, Vol 7, No 1
2017
December 2017, Vol 6, No 5
October 2017, Vol 6, No 4
August 2017, Vol 6, No 3
June 2017, Vol 6, No 2
April 2017, Vol 6, No 1
2016
December 2016, Vol 5, No 6
October 2016, Vol 5, No 5
August 2016, Vol 5, No 4
June 2016, Vol 5, No 3
April 2016, Vol 5, No 2
February 2016, Vol 5, No 1
Issues Archive
Supplements
Categories
Web Exclusives
All Web Exclusives
FDA Approvals, News & Updates
In The News
Online First
Videos
About
About VBCR
About Engage HC
Contact Us
Editorial/Publishing Policies
Editorial Board
Advertising Contacts
Advertising Policy
Author Guidelines
Friday, 29 March 2024
Authored Items
Characteristics of “Superutilizers” Among Patients with Schizophrenia
Charles Bankhead
VBCN - November 2016 Volume 3, No 3
in
Schizophrenia
Timing of Epilepsy Onset Influences Type of Cognitive Impairment and Memory Deficits
Charles Bankhead
VBCN - November 2016 Volume 3, No 3
in
Epilepsy/Seizures
One-Fourth of Eligible Patients with Stroke Still Not Receiving Thrombolytic Therapy
Charles Bankhead
VBCN - November 2016 Volume 3, No 3
in
Stroke
Loss of Independence Common Even in Early-Stage Parkinson’s Disease
Charles Bankhead
VBCN - November 2016 Volume 3, No 3
in
Parkinson’s Disease
More Evidence of Increased Mortality Risk in Patients with Rheumatoid Arthritis
Charles Bankhead
VBCR - October 2016, Vol 5, No 5
in
Rheumatoid Arthritis
Mixed Cost Results with Repository Corticotropin Injection Therapy for Patients with SLE
Charles Bankhead
VBCR - August 2016, Vol 5, No 4
in
Lupus
Creatine Boosts Muscle in Rheumatoid Arthritis, but Not Strength or Function
Charles Bankhead
VBCR - August 2016, Vol 5, No 4
in
Rheumatoid Arthritis
Chemotherapy Use in Breast Cancer Declines with Gene-Based Assay
Charles Bankhead
VBCC - June 2016, Vol 7, No 5
in
Value in Oncology
Mutation Testing Encouraged for All Patients with Ovarian Cancer
Charles Bankhead
VBCC - June 2016, Vol 7, No 5
in
Personalized Medicine
Novel Regimen Outperforms Standard Chemotherapy in HER2 Breast Cancer
Charles Bankhead
VBCC - June 2016, Vol 7, No 5
in
Breast Cancer
Slow Uptake of Minimally Invasive Surgery for Endometrial Cancer
Charles Bankhead
VBCC - June 2016, Vol 7, No 5
in
Gynecologic Cancers
Opioid Use Decreases in Gynecologic Cancer Surgery with Liposomal Bupivacaine
Charles Bankhead
VBCC - June 2016, Vol 7, No 5
in
Gynecologic Cancers
First-in-Class Stem-Cell Inhibitor Active in Pancreatic and Colorectal Cancers
Charles Bankhead
VBCC - May 2016, Vol 7, No 4
in
Gastrointestinal Cancers
Genomic Instability Score Predicts Survival in Patients with Ovarian Cancer
Charles Bankhead
VBCC - May 2016, Vol 7, No 4
in
Personalized Medicine
Drug-Refractory Tardive Dyskinesia Improves with Deep-Brain Stimulation
Charles Bankhead
VBCN - April 2016 Volume 3, No 1
in
Tardive Dyskinesia
Assessing the Value of Neurologist-Directed Patient Care
Charles Bankhead
VBCN - April 2016 Volume 3, No 1
in
Value in Neurology
Checkpoint Inhibitors Active in Gastric and Esophageal Cancers
Charles Bankhead
VBCC - April 2016, Vol 7, No 3
in
Gastrointestinal Cancers
Adjuvant Therapy at High-Volume Centers Improves Pancreatic Cancer Survival
Charles Bankhead
VBCC - April 2016, Vol 7, No 3
in
Gastrointestinal Cancers
Atezolizumab, a PD-L1 Inhibitor, Shows Impressive Results in Metastatic Urothelial Cancer
Charles Bankhead
VBCC - March 2016, Vol 7, No 2
in
Emerging Therapies
Biomarker Panel May Aid Early Detection of Colorectal Cancer
Charles Bankhead
VBCC - March 2016, Vol 7, No 2
in
Personalized Medicine
Increased Physical Activity May Help Extend Survival After Prostate Cancer Diagnosis
Charles Bankhead
VBCC - March 2016, Vol 7, No 2
in
Prostate Cancer
CAR T-Cell Therapy Highly Active in Various Lymphomas
Charles Bankhead
VBCC - February 2016, Vol 7, No 1
in
Lymphoma Highlights
Value of MRI in Smoldering Myeloma Stressed by the International Myeloma Working Group
Charles Bankhead
VBCC - May 2015, Vol 6, No 4
in
Multiple Myeloma
Revised Survivorship Care Plan Template Reduces Time and Resource Commitments
Charles Bankhead
VBCC - May 2015, Vol 6, No 4
in
Survivorship
PARP Inhibitor Maintenance Too Pricey for Ovarian Cancer?
Charles Bankhead
VBCC - April 2015, Vol 6, No 3
in
Gynecologic Oncology Highlights
Comprehensive Cancer Center Designation Trumps High Volume as Predictor for Outcomes in Ovarian Cancer
Charles Bankhead
VBCC - April 2015, Vol 6, No 3
in
Gynecologic Oncology Highlights
More Bad News for Erythropoiesis-Stimulating Agents in Chemotherapy-Induced Anemia
Charles Bankhead
VBCC - March 2015, Vol 6, No 2
in
Breast Cancer
Longer Neoadjuvant Therapy Boosts Response in HER2-Positive Breast Cancer
Charles Bankhead
VBCC - February 2015, Vol 6, No 1
in
Breast Cancer Symposium
Estrogen Receptor Antagonist Fulvestrant Tops Aromatase Inhibitor Anastrozole for ER-Positive Breast Cancer
Charles Bankhead
VBCC - February 2015, Vol 6, No 1
in
Breast Cancer Symposium
Cost-Effectiveness Analysis Shows Specialty Drugs Offer Value Despite High Cost
Charles Bankhead
VBCC - February 2015, Vol 6, No 1
in
Economics of Cancer Care
Big Jump in Spending for Oral Oncologics
Charles Bankhead
VBCC - December 2014, Vol 5, No 10
in
Economics of Cancer Care
New Data Show PFS, Survival Benefits with Bevacizumab in Breast Cancer
Charles Bankhead
VBCC - October 2014, Vol 5, No 8
in
ESMO 2014 Highlights
Mixed Results with Postprogression EGFR Inhibition in Advanced Non–Small-Cell Lung Cancer
Charles Bankhead
VBCC - October 2014, Vol 5, No 8
in
ESMO 2014 Highlights
Most Preoperative Breast MRIs Requested by Nononcologists
Charles Bankhead
VBCC - October 2014, Vol 5, No 8
in
Breast Cancer
Study Identifies Important Benefits of Cancer Survivorship Programs
Charles Bankhead
VBCC - October 2014, Vol 5, No 8
in
Breast Cancer
Cost Burden Follows Patients with Cancer into Survivorship
Charles Bankhead
VBCC - September 2014 Vol 5, No 7
in
Economics of Cancer Care
Smoking Still a Major Cause of Cancer Death: A Call to Action on Tobacco Control
Charles Bankhead
VBCC - June 2014 Vol 5, No 5
in
Health Policy
Veliparib, a PARP Inhibitor, Active in Recurrent BRCA-Positive Ovarian Cancer
Charles Bankhead
VBCC - June 2014 Vol 5, No 5
in
Ovarian Cancer
Large Study Supports Regionalization of Gynecologic Cancer Care
Charles Bankhead
VBCC - May 2014 Vol 5, No 4
in
Society of Gynecologic Oncology
Preventive Oophorectomy May Not Eliminate Risk for BRCA1-Related Uterine Cancer
Charles Bankhead
VBCC - May 2014 Vol 5, No 4
in
Society of Gynecologic Oncology
Multitargeted Kinase Inhibitor Shows Promise for Breast Cancer Subgroup
Charles Bankhead
VBCC - May 2014 Vol 5, No 4
in
AACR Annual Meeting
Highest Response in Metastatic Renal-Cell Carcinoma with Pazopanib, Third-Line VEGF Inhibitor
Charles Bankhead
VBCC - May 2014 Vol 5, No 4
in
AACR Annual Meeting
CDK 4/6 Inhibitor Slows Progression of Metastatic Breast Cancer
Charles Bankhead
VBCC - May 2014 Vol 5, No 4
in
AACR Annual Meeting
Imaging Choice May Influence Brachytherapy Outcomes
Charles Bankhead
VBCC - April 2014 Vol 5, No 3
in
Prostate Cancer
Promise of Personalized Care Hinges on Reimbursement Reform
Charles Bankhead
VBCC - April 2014 Vol 5, No 3
in
Economics of Cancer Care
Role of Nutrition in Parkinson’s Disease: Neuroprotective Effects Identified, but Definitive Evidence Still Lacking
Charles Bankhead
VBCN - April 2014 Volume 1, No 1
in
Parkinson’s Disease
Migraine Prevalence Rises with Decline in Income, but Remission Is Stable
Charles Bankhead
VBCN - April 2014 Volume 1, No 1
in
Health Economics
Previous Docetaxel Therapy Thwarts Enzalutamide Activity in CRPC
Charles Bankhead
VBCC - March 2014, Volume 5, No 2
in
Prostate Cancer
Systemic Therapy Wins One, Loses One in Head and Neck Cancer
Charles Bankhead
VBCC - March 2014, Volume 5, No 2
in
Head and Neck Cancer
Outpatient Chemoradiation Regimen Matches Inpatient Care Outcomes, at Lower Costs
Charles Bankhead
VBCC - March 2014, Volume 5, No 2
in
Head and Neck Cancer
Virtual Patients Help Identify Opportunities for Cost-Savings
Charles Bankhead
VBCC - March 2014, Volume 5, No 2
in
Pathways
Second-Generation Genomic Sequencing Offers Opportunities, Poses Challenges
Charles Bankhead
VBCC - February 2014, Volume 5, No 1
in
Personalized Medicine
PIK3CA Mutation Thwarts Neoadjuvant Anti-HER2 Therapy in Breast Cancer
Charles Bankhead
VBCC - February 2014, Volume 5, No 1
in
Personalized Medicine
Aromatase Inhibitor–Related Pain Reduced with Exercise Regimen
Charles Bankhead
VBCC - February 2014, Volume 5, No 1
in
SABCS 2014
Sulfasalazine Fails to Prevent Radiotherapy-Induced Diarrhea
Charles Bankhead
VBCC - November 2013, Volume 4, No 9
in
Radiotherapy in Focus
Expanded Radiotherapy Improves Breast Cancer Control
Charles Bankhead
VBCC - November 2013, Volume 4, No 9
in
Radiotherapy in Focus
Oral VEGF Inhibitor, Cediranib, Improves Survival in Recurrent Ovarian Cancer
Charles Bankhead
VBCC - November 2013, Volume 4, No 9
in
Ovarian Cancer
Development of Quality Measures Should Address Current Limitations
Charles Bankhead
VBCC - November 2013, Volume 4, No 9
in
ASCO Quality Care Symposium
Need for Innovative Strategies for Quality Care Will Continue to Grow
Charles Bankhead
VBCC - November 2013, Volume 4, No 9
in
ASCO Quality Care Symposium
Integrating Patient-Reported Outcomes into Cancer Care
Charles Bankhead
VBCC - November 2013, Volume 4, No 9
in
ASCO Quality Care Symposium
ASCO’s “Choosing Wisely” Top 5 List: Inappropriate Tests, Imaging, and Targeted Therapies
Charles Bankhead
VBCC - November 2013, Volume 4, No 9
in
ASCO Quality Care Symposium
Cost-Effective Strategy for Early NSCLC Hinges on Operability of the Disease
Charles Bankhead
VBCC - November 2013, Volume 4, No 9
in
Economics of Cancer Care
PET Use for NSCLC Management Has Altered Resource Utilization, Increased Cost
Charles Bankhead
VBCC - November 2013, Volume 4, No 9
in
Economics of Cancer Care
IOM Cites Looming Cancer Care Crisis, Recommends Course-Correcting Strategies
Charles Bankhead
VBCC - October 2013, Volume 4, No 8
in
Economics of Cancer Care
ASCO Adds Aromatase Inhibitor to Breast Cancer Prevention Options in Postmenopausal Women
Charles Bankhead
VBCC - September 2013, Volume 4, No 7
in
Breast Cancer
New Guideline Emphasizes Sequenced Therapy for Castration-Resistant Prostate Cancer
Charles Bankhead
VBCC - June 2013, Volume 4, No 5
in
Prostate Cancer
Companion Diagnostics Information Not Easily Obtained
Charles Bankhead
VBCC - June 2013, Volume 4, No 5
in
Personalized Medicine
AUA Revises Its Guidelines for Prostate Cancer PSA Screening
Charles Bankhead
VBCC - May 2013, Volume 4, No 4
in
Prostate Cancer
Ibrutinib Shows Rapid, Dramatic Responses in Patients with CLL
Charles Bankhead
VBCC - May 2013, Volume 4, No 4
in
AACR Annual Meeting
Palliative Care Cost-Effective for Platinum-Resistant Ovarian Cancer
Charles Bankhead
VBCC - May 2013, Volume 4, No 4
in
Economics of Cancer Care
Neoadjuvant Chemotherapy Reduces Costs for Older Patients with Ovarian Cancer
Charles Bankhead
VBCC - May 2013, Volume 4, No 4
in
Economics of Cancer Care
New Mantle-Cell Regimen Leads to “Remarkable” Response Rate
Charles Bankhead
VBCC - May 2013, Volume 4, No 4
in
AACR Annual Meeting
Positron Emission Tomography Scanning May Identify Stage I NSCLC that Requires Chemotherapy
Charles Bankhead
VBCC - May 2013, Volume 4, No 4
in
AACR Annual Meeting
Deviation from Clinical Guidelines Takes Toll on Ovarian Cancer Survival
Charles Bankhead
VBCC - May 2013, Volume 4, No 4
in
Ovarian Cancer
Tumor Subtype Fails to Explain Racial Disparity in Breast Cancer Survival
Charles Bankhead
VBCC - May 2013, Volume 4, No 4
in
Personalized Medicine
Gene Expression May Simplify Search for Effective Therapy in Head and Neck Cancer
Charles Bankhead
VBCC - May 2013, Volume 4, No 4
in
Personalized Medicine
Liquid Biopsy Improves Detection of Secondary GIST Mutations Causing Drug Resistance
Charles Bankhead
VBCC - May 2013, Volume 4, No 4
in
Personalized Medicine
No Loss of Efficacy with Anthracycline-Free Induction for Acute Lymphoblastic Leukemia
Charles Bankhead
VBCC - May 2013, Volume 4, No 4
in
Hematologic Malignancies
CHOP Disappearing as Standard of Care for Indolent NHL
Charles Bankhead
VBCC - May 2013, Volume 4, No 4
in
Hematologic Malignancies
Drug-Free Beads Match Chemoembolization for Hepatocellular Carcinoma
Charles Bankhead
VBCC - March 2013, Volume 4, No 3
in
Liver Cancer
Robotic Gastrectomy No Better, but More Costly, than Laparoscopic Surgery
Charles Bankhead
VBCC - March 2013, Volume 4, No 3
in
Health Economics
Hypofractionation Validated for Breast Radiotherapy: Less Potential for Toxicity Shown
Charles Bankhead
VBCC - March 2013 - San Antonio Breast Cancer Symposium 2012 Highlights
in
Radiation Therapy
Intraoperative Radiotherapy Fares Well Against EBRT
Charles Bankhead
VBCC - March 2013 - San Antonio Breast Cancer Symposium 2012 Highlights
in
Radiation Therapy
Gene-Based Test Identifies Breast Cancer with Low Risk for Late Metastasis
Charles Bankhead
VBCC - March 2013 - San Antonio Breast Cancer Symposium 2012 Highlights
in
Prognostic Tests
Preventive Therapy Preserves Sexual Function after Radiotherapy for Patients with Prostate Cancer
Charles Bankhead
VBCC - February 2013, Volume 4, No 2
in
Prostate Cancer
Infection Poses Lethal Risk Early in Patients with Multiple Myeloma
Charles Bankhead
VBCC - February 2013, Volume 4, No 2
in
ASH Annual Meeting
Local Ablation Extends Therapy Duration for Patients with NSCLC, Improves Disease Control
Charles Bankhead
VBCC - February 2013, Volume 4, No 2
in
Lung Cancer
Chemotherapy-Free Regimen Tops Standard for Treating Patients with Acute Promyelocytic Leukemia
Charles Bankhead
VBCC - January 2013, Volume 4, No 1
in
ASH Annual Meeting
“Dramatic” Responses with Targeted Agent for Patients with CLL
Charles Bankhead
VBCC - January 2013, Volume 4, No 1
in
ASH Annual Meeting
More Evidence Supports the Anticancer Effect of Metformin
Charles Bankhead
VBCC - October 2012, Volume 3, No 7
in
Breast Cancer Symposium
Fewer Women Undergo Mammography since Recent Task Force Recommendations
Charles Bankhead
VBCC - October 2012, Volume 3, No 7
in
Breast Cancer Symposium
Imaging Use in Breast Cancer Grows, Despite Evidence Gap
Charles Bankhead
VBCC - February 2011, Volume 2, No 1
in
Meeting Highlights
Triple-Negative Breast Cancer Has Highest Hospitalizations, Mortality Rates
Charles Bankhead
VBCC - February 2011, Volume 2, No 1
in
Meeting Highlights
FISH-Guided Therapy Balances Clinical Benefits and Cost
Charles Bankhead
VBCC - February 2011, Volume 2, No 1
in
Meeting Highlights
Ambulatory Care Key Financial Driver in Metastatic Breast Cancer
Charles Bankhead
VBCC - February 2011, Volume 2, No 1
in
Meeting Highlights
Cetuximab Adds Improvement in Triple Negative Cancer
Charles Bankhead
VBCC - Other
Significant Impact for New Prostate Cancer Therapy
Charles Bankhead
VBCC - November/December 2010, Volume 1, No 6
in
ESMO 2010 Conference
Benefit to Longer Chemotherapy in Metastatic Breast Cancer
Charles Bankhead
VBCC - November/December 2010, Volume 1, No 6
in
ESMO 2010 Conference
Last modified: October 7, 2010
Home
Issues
2018
April 2018, Vol 7, No 1
2017
December 2017, Vol 6, No 5
October 2017, Vol 6, No 4
August 2017, Vol 6, No 3
June 2017, Vol 6, No 2
April 2017, Vol 6, No 1
2016
December 2016, Vol 5, No 6
October 2016, Vol 5, No 5
August 2016, Vol 5, No 4
June 2016, Vol 5, No 3
April 2016, Vol 5, No 2
February 2016, Vol 5, No 1
Issues Archive
Supplements
Categories
Web Exclusives
All Web Exclusives
FDA Approvals, News & Updates
In The News
Online First
Videos
About
About VBCR
About Engage HC
Contact Us
Editorial/Publishing Policies
Editorial Board
Advertising Contacts
Advertising Policy
Author Guidelines